Recent in vitro and in vivo studies on the therapeutic utility of inhibitors targeting the cyclin D1-associated kinases CDK4/CDK6 revealed promising results in various cancer types including neuroblastoma [59, 61]. The gene discussed is CDK4; the disease is neuroblastoma.